CAL
EPZM

Capital Analysts LLC’s Epizyme, Inc EPZM Stock Holding History

Capital Analysts LLC’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000
Closed -$12K – 828
2020
Q3 		$12K Hold
1,000
– – ﹤0.01% 576
2020
Q2 		$16K Hold
1,000
– – ﹤0.01% 501
2020
Q1 		$16K Buy
+1,000
New +$21.5K ﹤0.01% 477

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Capital Analysts LLC's EPZM Position: Q4 2020 in Review

Capital Analysts LLC sold out of Epizyme, Inc (EPZM) in Q4 2020, closing a stake of 1,000 shares — an estimated $12K sold.

Capital Analysts LLC first reported a position in EPZM in Q1 2020 and held it in 3 quarters. The position peaked at $16K in Q2 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

  • Capital Analysts LLC reported no remaining Epizyme, Inc position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 1,000 Epizyme, Inc shares in Q4 2020, an estimated $12K.
  • Capital Analysts LLC first reported a position in Epizyme, Inc in Q1 2020 and held it in 3 quarters.
  • Capital Analysts LLC's Epizyme, Inc position peaked at $16K in Q2 2020.
  • 137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.